WASHINGTON, DC—Newly reported data from the TRILUMINATE randomized trial provide more objective evidence in support of transcatheter edge-to-edge repair (TEER) in patients with symptomatic severe ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a novel transcatheter edge-to-edge repair device for the treatment of severe tricuspid ...
NEW ORLEANS -- Transcatheter edge-to-edge repair (TEER) of severely regurgitant tricuspid valves improved outcomes, largely in terms of quality of life, the TRILUMINATE Pivotal trial showed. That ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results